FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso · Senolytic peptide · FOXO4 peptide
A D-retro-inverso peptide that selectively induces apoptosis (programmed cell death) in senescent "zombie" cells. Based on a landmark 2017 Nature Medicine paper by van Deursen et al., it is one of the most targeted senolytic compounds under research.
What is FOXO4-DRI? A D-retro-inverso peptide that selectively induces apoptosis (programmed cell death) in senescent "zombie" cells. Based on a landmark 2017 Nature Medicine paper by van Deursen et al., it is one of the most targeted senolytic compounds under research.
How does FOXO4-DRI work? Senescent cells (cells that have stopped dividing) accumulate with age and secrete inflammatory factors (SASP — senescence-associated secretory phenotype). FOXO4-DRI disrupts the interaction between the FOXO4 protein and p53, which senescent cells rely on to survive. This triggers apoptosis specifically in senescent cells while leaving healthy cells unaffected.
Benefits of FOXO4-DRI: Selectively destroys senescent (zombie) cells; Reduces SASP-driven chronic inflammation; May reverse age-related physical decline; Restores fitness, coat density, and renal function in aging mice; One of the most targeted senolytic agents known; Potential for cancer, organ fibrosis, and age-related disease
FOXO4-DRI dosage: Standard research protocol: 5-10mg subcutaneous for 3 days per week, monthly. Based on 2017 Nature Medicine study using 5mg/kg in mice. Human dose extrapolation is uncertain.
FOXO4-DRI half-life: Hours
Research status: Research Only
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/foxo4-dri
Mechanism of Action
Senescent cells (cells that have stopped dividing) accumulate with age and secrete inflammatory factors (SASP — senescence-associated secretory phenotype). FOXO4-DRI disrupts the interaction between the FOXO4 protein and p53, which senescent cells rely on to survive. This triggers apoptosis specifically in senescent cells while leaving healthy cells unaffected.
Benefits
- Selectively destroys senescent (zombie) cells
- Reduces SASP-driven chronic inflammation
- May reverse age-related physical decline
- Restores fitness, coat density, and renal function in aging mice
- One of the most targeted senolytic agents known
- Potential for cancer, organ fibrosis, and age-related disease
Side Effects & Risks
- Limited human data — primarily mouse models
- Potential immune response to cleared senescent cells
- Must be cycled (not continuous) to allow system recovery
- Transient inflammatory response as senescent cells are cleared
Where to Buy FOXO4-DRI
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$149.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C lyophilized, 4°C reconstituted
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Preclinical Research & Reviews1
Targeted apoptosis of senescent cells restores tissue homeostasis
FOXO4-DRI peptide selectively induced apoptosis in senescent cells and restored physical fitness in aging mice.
Research Protocol
- Dose Range
- 5–10 mg
- Frequency
- 3 consecutive days, then break
- Cycle
- 3 days on, monthly cycles
- Half-Life
- Hours
- Routes
- subcutaneous injectionintravenous injection
- Notes
- Standard research protocol: 5-10mg subcutaneous for 3 days per week, monthly. Based on 2017 Nature Medicine study using 5mg/kg in mice. Human dose extrapolation is uncertain.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About FOXO4-DRI
What is FOXO4-DRI?▾
A D-retro-inverso peptide that selectively induces apoptosis (programmed cell death) in senescent "zombie" cells. Based on a landmark 2017 Nature Medicine paper by van Deursen et al., it is one of the most targeted senolytic compounds under research.
What are the benefits of FOXO4-DRI?▾
Selectively destroys senescent (zombie) cells
What are the benefits of FOXO4-DRI?▾
Reduces SASP-driven chronic inflammation
What are the side effects of FOXO4-DRI?▾
Limited human data — primarily mouse models
What is the recommended dosage for FOXO4-DRI?▾
Standard research protocol: 5-10mg subcutaneous for 3 days per week, monthly. Based on 2017 Nature Medicine study using 5mg/kg in mice. Human dose extrapolation is uncertain.
How long should a FOXO4-DRI cycle last?▾
3 days on, monthly cycles
More Anti-Aging & Longevity Peptides
View all Anti-Aging & Longevity peptides →Livagen
KEDA tetrapeptide
A synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator series that de-heterochromatinizes age-condensed chromatin in lymphocytes, restoring youthful gene expression patterns. Hepatoprotective and immunomodulatory. One of the most mechanistically unique anti-aging peptides — it directly reactivates genes silenced by chromatin condensation with age.
Thyreogen
Thyroid peptide bioregulator
A thyroid-targeting tetrapeptide bioregulator from the Khavinson series. Normalizes thyroid cell function, thyroid hormone synthesis, and thyroid morphology. Studied for hypothyroidism, autoimmune thyroiditis, and thyroid aging. One of the most widely used Khavinson organ bioregulators given the high prevalence of thyroid dysfunction.
Ventfort
Vascular wall peptide bioregulator
A peptide bioregulator targeting blood vessel walls from the Khavinson series. Normalizes vascular endothelial cell function, reduces oxidative damage to vessel walls, and improves microcirculation. Distinct from Vesugen (which is the synthetic tripeptide form) in being the natural extract-based vascular bioregulator complex.
Vilon
Lys-Glu
A synthetic dipeptide from the Khavinson bioregulator series. Primarily acts as a thymus and immune regulator with demonstrated anti-aging properties.